most prominent inflammatory cytokine involved in CD is TNF-a which suppresses adhesion molecule expression and generates apoptosis in epithelial cells (6) , induces genes responsible for leukocyte recruitment (7) , and promotes a significant change in the function of the inflamed mucosal endothelium (8) . Among others, TNF-a regulates (negatively) the synthesis of nitric oxide (NO) by endothelial nitric oxide synthase (9) which, in turn, is required for maintaining proper blood flow, inhibits platelet aggregation and leukocyte adhesion, hence protects from atherosclerosis. NO also inhibits apoptosis and serves as a key factor in vascular endothelial growth factor (VEGF)-induced endothelial proliferation (10) (11) . Dysfunction of the vasodilatory capacity of microvessels derived from areas of chronic inflammatory damage was shown in lED (12) , and recently we found the deficiency ofeNOS expression in the microvasculature of tissue specimen of CD (13) and also in endothelial cells incubated with patients' sera (13, 15) which was associated with the formation of an extra number of unshaped microvessels (13) and enhanced VEGF production (15) . On the other hand, eNOS proved significant in endothelial protection in experimental colitis models (16) .
Drugs contanung anti-TNF-a antibody (infliximab) have already been introduced to clinical therapy of CD patients for a decade (17) and were also applied successfully in our practice recently (18) . By infliximab therapy the interaction between intestinal microvessels and T cells was disrupted (19) and blood flow parameters in large vessels were restored, (20) suggesting a beneficial effect of TNF-a neutralization on endothelial function in CD mucosa. Considering that TNF-a had a strong impact on the endothelium and the anti-TNF-a therapy of CD patients was helpful to the endothelium of the inflamed mucosa, we aimed to study the expression ofeNOS and VEGF receptor 2 (VEGFR2), two major indicators of endothelial function, in endothelial cells exposed to serum of CD patients after infliximab therapy. We used human umbilical vein endothelial cells (HUVEC) which are an accepted model to mimic in vivo microvascular responses in pathological conditions of the gastrointestinal tract (21) . HUVEC expresses eNOS, sensitive to TNF-a and regulated by NO (22) .
MATERIALS AND METHODS

Infliximab therapy ofCrohn :s patients
Patients with moderate to active CD undergoing first infliximab therapy were studied. The diagnosis of CD was confirmed by clinical, radiological, endoscopic, and histological criteria. The patients' clinical activity was determined by the CD activity index (COAl). A group of Crohn's patients of 25 subjects, considered clinically homogenous (patients data are presented in Table I ) and a group of 21 healthy subjects matched for age and sex was studied as control. Blood samples were collected from CD patients before and 24 h after infliximab (5 mg/kg, Centocor Ortho Biotech Inc., Horsham, PA, USA) infusion.
Collection ofumbilical cord and blood samples
Umbilical cords were collected from the local maternity hospital (Department of Obstetrics and Gynecology, MHS Center, University of Debrecen) during/after normal deliveries, whereas blood samples were collected from the 2nd Department of Gastroenterology, MHS Center, University of Debrecen. Ten milliliters of blood were taken from control subjects and patients with CD, respectively, into an anticoagulant-containing sterile tube. For experiments, the blood was centrifuged at 2000 g for 10 min, and the sera were removed and kept frozen at -80Co until use. For cytokine measurements, blood samples were centrifuged with 1000 g for 10 min and sera were kept at -20°C until use. In order to get an applicable volume of incubation media for the in vitro experiments, a mixture of sera collected from 5 individuals (healthy, non-Crohn controls; Crohn's patients; and infliximab-treated Crohn's patients) were prepared respectively.
Isolation and treatment ofHUVEC
The isolation and in vitro culture of HUVEC was described elsewhere (14) . Briefly, HUVEC was removed from umbilical cord with 1% collagenase type XI (Sigma-Aldrich, Budapest, Hungary) digestion, and cultured in a standard medium, containing M199 (Sigma-Aldrich) supplemented with 20% fetal calf serum (FCS) (Gibco, London, UK), 1% Amphotericin-B (Sigma-Aldrich), 1% Penicillin-Streptarnicyn (Gibco) and 1% L-glutamine (Gibco), in CO 2 incubator at 37°C. After 4-5 days of culturing, when cells grew over the entire surface of the dish, they were trypsinized and inoculated into new culture dishes. After 4 passages those cell monolayers which reached up to 80%-90% confluency were used for the experiments. HUVEC were incubated for 2,6, 12,24, 48 hours in the presence of various medium and serum combinations: a) medium containing 50% human serum collected from healthy volunteers; b) medium supplemented with 50% CD serum before intliximab therapy; c) medium containing 50% CD serum after infliximab therapy; d) medium containing 50% CD serum supplemented with infliximab (15 ng/mL) after 24 h incubation; e) medium supplemented with infliximab (15 ng/mL); f) medium supplemented with 20 ng/mL human recombinant TNF-a (Preprotech, Rocky Hill , NJ); g) medium containing 20 ng/mL human recombinant TNF-a supplemented with infliximab (15 ng/mL) after 24 h incubation.
Each combination was in standard medium. When the medium was substituted by human serum (a-d), FCS was omitted.
To assess the direct effect of infliximab on HUVEC we added 15 ng/mL infliximab to the standard medium (e), and after 24 h pretreatment with standard medium containing 50% CD serum (d), or 20 ng/mL human recombinant TNF-a (g), respectively. In previous experiments the threshold concentration ofTNF-a, which affected eNOS level , but still did not induce cell death, was established at 20 ng/ml. Infliximab was tested in vitro in a range 5-1000 ng/mL, and 15ng/mL was found suitable to block TNF-a in the serum or used natively in standard medium. At higher concentrations infliximab did not produce significant differences in the results.
Flow cytometry
To analyze the phenotype of HUVEC, the cells were collected at passage 5 by brief exposure to 0.025 % Table I . Clinical data ofpatients with Crohn sdisease. tryspin/l mM EDTA (Invitrogen Corp , Carlsbad, CA) and washed twice in ice cold phosphate buffered 0.9% saline containing 5 mM EDTA and 5% BSA (FACS buffer). Approximately 3x I0 5 cells were suspended in a final volume of 40 III of FACS buffer and incubated with a primary antibody for 30 m on ice. The cells were washed again twice with FACS buffer and suspended in a final volume of 400 III for flow cytometric analysis. The following primary antibodies were used: anti-CD29-FITC, anti-CD31-FITC/PECAM-1, anti-CD 105, anti-CDl44NE-Cadherin, anti-VEGFR2/KDR-FITC (R&D Systems, Minneapolis, MN , USA), anti-CD45 , anti-CD90, anti-CD106 (BD Biosciences, San Jose , CA), CD133-APC (Miltenyi Biotech, University Park, PA), and the matching isotype controls as well. Acquisition was carried out using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Data analysis was performed using Cell Quest Pro v5.2 (BD Biosciences). At least 200,000 cells per sample were acquired, and analysis was considered informative if more than 100 events had been collected.
Western blot
HUVEC was washed with ice-cold phosphate-buffered saline (PBS , pH 7.2), then harvested by a cell scraper and transferred to lysis buffer (standard RIPA) containing freshly added protease inhibitors (aprotinin, leupeptin, pepstatin A, bestatin, p-amidinophenylrnethanesulfonyl fluoride [p-AMSF]). Cell lysis was performed by 30 min incubation on ice. Samples were centrifuged with 12.500 rpm at 4°C for 10 min , then frozen and kept at -80°C until use. From each solution, aliquots (20 ul Isolation ofRNA from HUVEC Before RNA isolation HUVEC was washed 2 times with PBS. We used TRISOL reagent (Invitrogen/Gibco, London, UK) to extract the total RNA according to the manufacturer's instructions. The concentration and homogeneity of the RNA preparations were determined by measuring the absorbance of the sample at 260 nm and 280 nm by a spectrophotometer (Nanodrop, ND 1000; Thermo Fisher Scientific Inc., Wilmington, DE).
Quantification ofeNOS mRNA with RT Q-PCR
Reverse transcription of 100 ng of total RNA was carried out at 42°C for 1 h and at noc for 5 min by using the High Capacity eDNA archive Kit (Applied Biosystems, Foster City, CA). Real time quantitativepolymerase chain reaction (RT Q-PCR) was performed in an ABI SDS 5700 equipment (Applied Biosystems, Foster City, CA) under the following conditions: in 25 III sample 40 cycles at 94°C for 12 s and 60°C for 1 min by using TaqMan assay (Applied Biosystems). All PCR reactions were run in triplicate, parallel with one control reaction, in which the sample did not contain the reverse transcriptase. The comparative C, method was used to quantify the transcripts. The expression level of eNOS mRNA was normalized to transcript number of the human housekeeping gene h36B4. The results indicated that both gene products were equally suitable for being a reference; their synthesis did not change during experiments. Moreover, data obtained from using either 36B4 proved to be identical. All data were analyzed with SDS 2.1 software equipment (Applied Biosystems, Foster City, CA, USA). The oligonucleotide sequences and the specific fluorescence-labeled DNA probes were selected to span exon junctions of the target genes. The ASC eNOS/nos3 ABI-TaqMan Gene Expression assay (HsOOI67166_m1. Applied Biosystems, Foster City, CA) was used in the study.
Cytokine measurement
To quantify the free TNF-a concentration in patients' sera we used the OptEIA Human TNF Set (BD Pharmingen, BD Biosciences, San Jose, CA). The concentration of secreted angiogenic cytokines (VEGF, bFGF, angiogenin) in the cell culture supernatant of HUVEC was determined by CBA Cytokine Flex bead sets (BD Biosciences, San Jose, CA, USA). At the end ofeach experiment cell culture supernatant was collected and stored at -80°C until measurement. The concentration of cytokines was measured according to the manufacturer's instruction. The detection limit ofthe assay was 2.0 pg/ml for TNF-a, 4.5 pg/ml for VEGF, 4.6 pg/ml for angiogenin, and 3.4 pg/ml for bFGF, respectively.
Statistical analysis
Means of the percentages obtained from four independent experiments were presented in figures as mean±SEM. The significance of the data between treatment groups (a-g) was tested by analysis of variance (ANOVA). Significant differences between data within a group were evaluated using the Student's t-test. Differences were considered significant for values of P < 0.01.
Ethical considerations
Institutional ethical review board approval for the collection of umbilical cord samples from healthy human volunteers and informed consent regarding the experimental use of the cells from the volunteers as well collection of peripheral blood samples from healthy human volunteers and patients with CD were obtained.
RESULTS
Determination ofHUVEC sphenotype
We tested all HUVEC samples under normal conditions at 80-90% confluency for CD29, CD31, CD105, CD144 (VE-Cadherin), CD45, CD133, CD90, CD106, VEGFR2 expression by flow cytometry (Fig. 1 ). Markers characterizing endothelial cells such as CD29, CD31, CDI05 and CDl44 were expressed in HUVEC. No hematopoietic contamination was detected, as judged by the negative results with the CD45 and CD133 markers. Fibroblast or smooth muscle cell contamination indicated by CD90 was not observed. Stress and/or activation markers such as CDI06 (VCAM-l) and VEGFR2/KDR were not detectable in the samples. If positivity for these markers were found, those samples (activated cells) were excluded from the experiments. Flow cytometric analysis confirmed that HUVEC contained only non-activated and uncommitted, morphologically and functionally typical endothelial cells.
Effect ofirfliximab therapy on level ofsoluble TNFa in the blood
The pro-inflammatory cytokine TNF-a has been considered to be at least partly responsible for the maintenance of inflammation in Crohn's disease (23) . The average concentration of TNF-a in the serum of Crohn's patients was 34.20±5.80 pg/mL (Fig. 2) . Twenty-four hours after infliximab therapy, TNF-a concentration in the sera of Crohn's patients decreased to 0.61±0.06 pg/ml, which was significantly lower than was found before medication. This cytokine level was almost identical to that detected in healthy individuals (0.58±0.04 pg/ml) and was under the method limit.
Effect of irfliximab therapy on the expression of eNOS protein in cultured HUVEC eNOS protein is expressed in HUVEC cultured in the presence of 50% human serum obtained from healthy volunteers as detected by Western blot (Fig.  3A) . Intensity of the eNOS-IR bands remained high during the 48 h incubation period and the relative (14) . Sera obtained from active Crohn's patients, who underwent infliximab therapy, could entirely (~100%) recover eNOS protein level in cultured HUVEC, as demonstrated at each time point measured (Fig. 3C ). This implies that no significant differences could be found when the data were compared to the 0 time point or to the corresponding data point as shown in Fig. 3A (p>0.05; n=4 ). Infliximab (15 ng/mL) could also increase the expression of eNOS protein in HUVEC in vitro when it was added to the cultured cells after 24 h of treatment with medium containing active Crohn's sera (Fig. 3D ). The level of eNOS protein could be recovered within 2 h and remained constant for 48 h. When 15 ng/mL infliximab was given directly to HUVEC cultured in normal serum no significant change was detected in eNOS level ( Fig. 3E ) compared to controls (Fig. 3A) . Addition of 20 ng/ml TNF-a to cultured HUVEC reduced eNOS levels by approx. 40% after 2 h which then remained low throughout the experiment (Fig. 3F ). The level of eNOS was proved to be significantly lower when compared to either the 0 time point or to the corresponding control in Fig. 2A (p<0.05; n=4 ). When 15 ng/mL infliximab was added to cultured HUVEC pre-incubated with 20ng/ml TNF-a for 24 h (Fig. 3G) , eNOS levels were slightly elevated but did not reach control levels (see Fig. 3A ), and did not show any significant difference as compared to the treatment with TNF-a alone (see Fig. 3F ).
The effect of infliximab therapy on eNOS expression by HUVEC was also studied using individual Crohn's sera ( Fig. 4 ). Postinfusion serum (5 mg/kg infliximab) of a patient with good clinical response (patient "a") after 2 weeks induced eNOS recovery after 24 h (Fig. 4A ). However, no clinical response was observed in another patient (patient "b") who was clinically refractory to infliximab treatment, and the addition of this serum could not modulate eNOS protein levels in HUVEC (Fig.  4B) .
Effect of infliximab therapy on the expression of eNOS mRNA in cultured HUVEC
The relative expression of eNOS mRNA was measured by RT Q-PCR and was related to the h36B4 house-keeping gene. Analysis of eNOS mRNA expression revealed that HUVEC cultured in the presence of 50% control (healthy) serum remained low throughout the 48 h culture period (Fig. SA) . Replacing the control serum with 50% Crohn's serum did not influence eNOS mRNA levels for 12 h (Fig. 5B ), but thereafter a dramatic increase of eNOS mRNA level was observed that peaked at 48 h with a ll-fold increase as compared to control (Fig. SA, p<0.05; n=4 ). Serum ofCrohn's patients pretreated with infliximab resulted in eNOS mRNA upregulation with two peaks at 2 hand 24 h, where the expression of mRNA levels significantly exceeded control level by 12-and 6-fold, respectively (Fig. 5C, p<0.05; n=4 ). Before and after these time points eNOS levels were similar to control. After incubation of HUVEC with Crohn's serum for 24 h and afterward with IS nglml infliximab (Fig. 5D,) the changes of eNOS mRNA levels were similar to that found with Crohn's serum (Fig. 5B) , however the extent of the increase of the eNOS mRNA level at 48 h was obviously less. Infliximab itself did not affect eNOS mRNA expression ( Fig. 5E ). Twenty ng/ml TNF-a induced immediate eNOS mRNA expression by approx. 3-fold, which then decreased continuously with time ( Fig. 5F) , and resulted in a similar mRNA level as that found in the control after 12 h incubation (see Fig. 5A ). In vitro administration of 15 ng/ml infliximab to cultured HUVEC significantly reduced TNF-a (20 ng/ml)-evoked eNOS mRNA induction at early time points (up to 6 h) investigated, however, later the mRNA level were comparable to the control (Fig. 5G, p<0 .05, n=4).
Effect of infiiximab therapy on the expression of VEGFR2 protein in cultured HUVEC
VEGFR2 is known to be dependent on eNOS synthesis (24) . To assess the expression ofVEGFR2 in cultured HUVEC we used the Western blot technique. No VEGFR2 expression was detected in HUVEC kept in control medium ( Fig 6A) . In the presence of 50% Crohn's serum, an immediate elevation of VEGFR2 expression was observed shortly after the onset of incubation, then an intermittent but elevated receptor expression was induced (Fig. 6B, p<0.05;  n=4 ). The highest VEGFR2 protein expression was detected at 6 and 24 h. Sera obtained from Crohn's patients treated with infliximab ( Fig. 6C ) were able to keep VEGFR2 levels significantly lower than those measured in untreated patients (see Fig. 6B , p<0.05; n=4). Enhanced expression of the receptor was found only at 24 h of incubation. When infliximab (15 ng/ml) was added in vitro to cultured HUVEC incubated for 24 h with Crohn's serum, VEGFR2 expression was only slightly decreased during the experimental period ( Fig. 6D ) compared to Fig. 6B . Infliximab itself at 15 ng/ml concentration was not able to induce VEGFR2 synthesis in vitro (Fig. 6E ). Addition of 20 ng/mL TNF-a to cultured HUVEC evoked an immediate and permanent induction of VEGFR2 synthesis within the 48 h time window (Fig.  6F) , whereas infliximab could restore low VEGFR2 expression in HUVEC after 12 h incubation, when infliximab was given to the incubation medium that contained 20 ng/ml TNF-a and had been applied to HUVEC for 24 h (Fig. 6G) .
The level ofangiogenic cytokines in the supernatant ofHUVEC after infiiximab therapy
Deficiency of eNOS expression In the microvasculature of colonic mucosa obtained from Crohn's patients was previously suggested to contribute to increased proliferation-induced neovascularization (13, 15) . The supernatant of HUVEC cultured in control medium containing 50% pooled serum from healthy subjects (a) contained hardly any angiogenic cytokines: after 24 h incubation only angiogenin was detected at 3.56±0.04 ng/ml concentration (Fig. 7) . Following treatment with medium supplemented with the serum of active Crohn's patients (b) the angiogenin concentration was reduced to 2.9±0.035 ng/ml, while the concentration of VEGF and bFGF increased to 204.5±12.9 and 166.7±13.9 pg/ml, respectively. When sera ofpatients treated with infliximab infusion (c) were added to HUVEC, the concentration of angiogenin and bFGF remained at control levels (angiogenin was 3.3±0.1 ng/ml; bFGF was under the detection limit), whereas VEGF concentration (80.1±23.8 pg/ml) was significantly less than before medication. Note that angiogenic cytokines could not be detected in the sera before incubation with HUVEC.
DISCUSSION
In this study a model system was established to evaluate the effect of infliximab therapy on the repair ofblood vessels in the inflamed CD mucosa by testing the response of primary HUVEC cultured in vitro. We monitored the expression of eNOS and VEGFR2, two major indicators of endothelial cell state and function, by mRNA and protein levels. We found that the serum of Crohn's patients, which contains an elevated level ofTNF-a, and the proinflammatory cytokine TNF-a itself, are capable of reducing eNOS protein levels, with a simultaneous induction of VEGFR2 expression in cultured HUVEC. When HUVEC is incubated in sera obtained from patients previously treated with infliximab, the expression level of these proteins tends to those data obtained from experiments with healthy (normal, control) serum. Moreover, infliximab therapy decreases not only the high level of TNF-a in Crohn's serum, but also leads to the reconstitution of normal angiogenic cytokine levels produced by the endothelium. Thus, here we demonstrate in vitro the direct healing effect of infliximab on the endothelium, that also suggests protection and functional recovery of the mucosal microvasculature in vivo as a result of anti-TNF-a therapy. Our results support previous reports demonstrating that TNF-a inhibitors improve endothelial functions in vivo (20, 23, (25) (26) .
Serum TNF-a level of CD patients indicates that patients are in the inflamed state of the disease, and it is well consistent with the range found in other population (27) . Comparing to the application of Crohn's serum, pure TNF-a evokes a similar but more rapid reduction ofthe eNOS protein level which can be the consequence of the known destabilization effect of TNF-a on eNOS mRNA (28) . Difference in the velocity, degree and temporal changes of the response might be due to the lower concentration but enhanced stability of TNF-a in Crohn's serum. Blocking TNF-a in vivo by infliximab therapy and also in vitro by administering infliximab to the medium preincubated with Crohn's serum proves to be beneficial to the recovery of eNOS. Therefore, based on these findings, and in good accordance with previous results (29) , the eNOS protein level of HUVEC is downregulated by TNF-a. It is evident however, that infliximab, dissolved either in Crohn's serum or in TNF-a supplemented medium, bears less potential to elicit recovery of eNOS protein and mRNA, and also VEGFR2 versus in vivo application. Presumably, replacing TNF-a alone is not sufficient for HUVEC to repair eNOS synthesis and to downregulate VEGFR2. In the case of incubation with TNF-a, it can not be excluded that the applied amount of infliximab does not neutralize all TNF-a molecules in the medium. Notably, the adjustment ofTNF-a and infliximab concentration is difficult in experimental design d, f, and g, because of the instability and rapid decomposition of these molecules. Elevation of the eNOS mRNA copy number after 24 h incubation with the Crohn's serum suggests an endogen inclination to restore the eNOS level, whereas infliximab therapy evokes eNOS mRNA synthesis much earlier, indicating the rapid reproduction of eNOS. VEGFR2 expression is rapidly elevated in HUVEC exposed to Crohn's serum, or to TNF-a which is supported by literature data (30) . Decreases in the VEGFR2 .level after 12 h incubation with Crohn's serum is parallel with the inhibition of eNOS expression, suggesting a common mechanism evoked by TNF-a. jn the reduction ofthese proteins, which was also confirmed earlier (24) Considering the limitations of our in vitro approach we conclude that infliximab treatment -and consecutive reduction of TNF-a level -may have beneficial effects on the restoration of endothelial dysfunction characterized by altered eNOS production that plays a role in the initiation and perpetuation of inflammatory processes in IBD. Our experiments carried out in culture media containing individual patient's sera indicate a recovery on eNOS production of HUVEC that was detected in those cases only, in which the clinical response was proved to be significantly better later on. The prognostic efficacy of these observations however, needs further confirmation.
